Clinical trial · Interventional
Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Endoesophageal Brachytherapy for Patients With Esophageal Cancer: A Balloon Repositioning, Multichannel Radiation Applicator for Optimizing Treatment Delivery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Depending upon the cancer stage, esophageal cancer can be treated with surgery, chemotherapy, radiation therapy, or a combination of these modalities. Sometimes in addition to external radiation therapy or instead of external radiation therapy, select patients with esophageal cancer may benefit from localized radiation to the tumor, called esophageal brachytherapy. There are many different radiation techniques and delivery approaches for this type of specialized radiation therapy, and the purpose of this document is to provide a written summary of an innovative delivery method.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoesophageal Brachytherapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- brachytherapy with multichannel balloon applicator
- description
- 6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
- interventionNames
- Device: Endoesophageal Brachytherapy
Primary outcomes (2)
- measure
- Dose of Radiation Delivered to 90% of Tumor Volume (D90)
- timeFrame
- Up to 6 months of follow-up
- description
- Percent of prescription dose received by 90% of PTV (planning target volume)
- measure
- Percent Volume of the Tumor Receiving the Prescription Dose (V100)
- timeFrame
- Up to 6 months of follow-up
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proved esophageal adenocarcinoma or squamous cell carcinoma * Disease that can be encompassed in the radiotherapy treatment field * Women of childbearing potential must practice adequate contraception * Subjects must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Concurrent chemotherapy at the time of brachytherapy treatments * Tracheal or bronchial involvement * Cervical esophagus location * Stenosis that cannot be bypassed or dilated to allow for applicator placement * Not willing or unable to provide informed consent * History of esophageal fistula
References
Publications (0)
Data not yet available